-
December 11, 2017
Aileron Therapeutics Presents New Data on ALRN-6924 in Oral Presentations at 2017 American Society of Hematology Meeting
-
November 9, 2017
Aileron Therapeutics Reports Third Quarter 2017 Financial Results
-
November 1, 2017
Aileron Therapeutics Announces Oral Presentations on Lead Product Candidate ALRN-6924 at the 59th American Society of Hematology Annual Meeting
-
September 19, 2017
Aileron Therapeutics Added to the Russell 2000, Russell 3000 and Russell Microcap Indexes
-
August 24, 2017
Aileron Therapeutics Announces Presentation of Preclinical Data with ALRN-6924 at the International Society of Experimental Hematology Annual Scientific Meeting
-
August 10, 2017
Aileron Therapeutics Reports Second Quarter 2017 Financial Results
-
August 3, 2017
Aileron Therapeutics to Present at Canaccord Genuity 37th Annual Growth Conference
-
June 28, 2017
Aileron Therapeutics Announces Pricing of Initial Public Offering
-
June 15, 2017
Aileron Therapeutics Appoints Donald Dougherty as Senior Vice President and Chief Financial Officer
-
June 3, 2017
Anti-tumor Activity Observed in Phase 1 Trial of Novel P53-Targeting Drug ALRN-6924